Skip to content
Search our Site
Search our site
Search our site
About the EPDA
Political affairs and policy
Resources and publications
All research papers
Search research papers
Medication research papers
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study
Impulse control disorders (ICDs) encompass a wide spectrum of abnormal behaviour frequently found in cases of Parkinson's disease (PD) treated with dopamine agonists (DAs). The main aim of this study was to analyse ICD prevalence with different DAs.
01 August 2014
Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial
There was a significantly greater reduction in the off-time (p = 0.014) in the rotigotine group. Rotigotine was well tolerated, with serious adverse events being reported in only three patients in each group. Rotigotine at doses of up to 16 mg/24 h is efficacious and safe in Japanese patients with advanced PD.
18 July 2014
Naltrexone for impulse control disorders in Parkinson disease
Naltrexone treatment was not efficacious for the treatment of ICDs in PD using a global assessment of response, but findings using a PD-specific ICD rating scale support further evaluation of opioid antagonists for the treatment of ICD symptoms in PD.
18 July 2014
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Authors conclude that motor fluctuations and dyskinesias are not associated with the duration of levodopa therapy, but rather with longer disease duration and higher levodopa daily dose. Hence, the practice to withhold levodopa therapy with the objective of delaying the occurrence of motor complications is not justified.
17 July 2014
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease
This 2-year, controlled study of add-on safinamide in mid-to-late Parkinson's disease with motor fluctuations, although not demonstrating an overall difference in dyskinesias between patients and controls, showed improvement in dyskinesia in patients at least moderately dyskinetic at baseline. The study additionally demonstrated significant clinical benefits in ON-time (without troublesome dyskinesia), OFF-time, activities of daily living, motor symptoms, quality of life, and symptoms of depression.
10 July 2014
Tozadenant (SYN115) in patients with Parkinson's who have motor fluctuations on levodopa: phase 2b, double-blind, randomised tri
Authors conducted an international, multicentre, phase 2b, randomised, double-blind, placebo-controlled, parallel-group, dose-finding clinical trial of tozadenant in levodopa-treated patients with Parkinson's disease who had motor fluctuations (at least 25 h off-time per day).
07 July 2014
Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson's disease
Study data are in agreement with (a) the Continuous Dopaminergic Stimulation (CDS) theory which states that continuous stimulation of the basal ganglia enhances motor, psychiatric and cognitive functions in PD patients and/or (b) findings that MAO-I increase the bioavailability of monoamines that have beneficial effects on motor and behavioral dysfunction in PD.
05 July 2014
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism
Study results suggest that sigma-1 receptor regulates endogenous defence and plasticity mechanisms in experimental parkinsonism. Boosting the activity of this protein may have disease-modifying effects in Parkinson's disease.
01 July 2014
Pramipexole reverses Parkinson's disease-related motivational deficits in rats
This longitudinal preclinical study provides evidence for the implication of the DA nigrostriatal system in PD-associated apathy. Moreover, by showing a good isomorphy and predictive value, our model highlights the relevance of D2/D3 receptors as potential targets for alleviating apathy in PD.
15 June 2014
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease
Results demonstrated a significantly greater improvement in total UPDRS scores from baseline to week 18 in the rasagiline group compared with the placebo group (least squares [LS] mean difference SE, 2.4 0.95; 95% confidence interval [CI], 4.3, 0.5; P = 0.012).
11 June 2014
Back to Top
Add page to PDF basket
Copyright © 2014 EPDA. All Rights Reserved.
Privacy and cookies